Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
about
Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohortShort and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study.Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infectionve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogensBoceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Treatment of hepatitis C in difficult-to-treat patients.Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.Economic study of the value of expanding HCV treatment capacity in Germany.Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.Sofosbuvir/Velpatasvir in Patients With Hepatitis C Virus Genotypes 1-6 and Compensated Cirrhosis or Advanced Fibrosis.The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevirThe hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients.Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments.[Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.
P2860
Q30244361-9F132F95-CEA4-4A30-B443-DF6462F70565Q33576871-309D4E58-438B-41EF-AD03-484969633518Q33775903-58B1CD60-8A45-4A96-A989-7FF17F12DCC9Q35164782-A7312219-A957-4AE1-893E-1119FBC60FE3Q35553310-0BDC0522-7547-4756-9CB3-B2A414788543Q35783876-7086A65B-5F85-446C-B425-3783F3BA1C59Q35928048-7C755A9E-1A98-4576-82EA-4EF406527D7BQ36098496-383FC06C-3949-4506-845A-DB73E81903A0Q36123998-C8883CDF-1C99-4349-BB96-7675D1AE8AEFQ36479541-281865A8-68DD-4EBF-8AA4-192F9E5B60EFQ36505470-9906AF11-F6AF-435A-A5A2-D7477B192352Q36766590-7EEC2E64-0521-4E3F-B67E-D026E03850C7Q37157057-9EDBA435-0585-400C-820F-149F4D9315A6Q37223591-09A6632D-0B4D-4FFA-B966-E3868A32E665Q37552703-42642B86-F4E8-4E6F-8699-023D92A4611FQ38431523-53462157-875B-47E6-9474-CF2DF04AC5DCQ38548066-3DFFF7D8-DCD8-47D2-BEE1-F752F934D7D2Q38688748-42C27CB1-5769-45C3-AFBD-9F887E213060Q38786027-BB42F37F-0ED7-4B73-8AC8-29894D302767Q38806255-F32A2477-952B-41C9-A8A2-39BD6ECCB015Q38876302-9A33CDC9-AA64-40AD-A31B-1B2C5B81E951Q39010715-462A2748-84D3-4FAE-A573-3BECA2D3D7A7Q39058953-8A5B2F6E-9317-4A5D-BD3B-EE6EB5969FDEQ39449507-B2DEB8F6-7923-4A7D-AE58-EBC78238BDE0Q39821108-2B48125D-6EB8-48B3-A3DF-5E026776C3A1Q40102621-2B30AD94-113D-4BFA-BD69-B63E295F635AQ40215846-884B84F3-D4E2-44A9-BBE0-74EA9681E1A5Q40690097-CDB8A67A-54F4-491E-8794-57CE4905BF25Q40774514-3F2C1139-E044-4C24-A244-239999FF32AEQ40795101-C2738A86-2F17-44D4-B8B9-DC7F9566D080Q41042403-6B116F28-4A39-4600-A1CE-FD063DDC9933Q41469280-447E79FC-48BC-45BA-8810-F2AF91587278Q47202796-1C65039F-6DDE-4D1B-BBBF-46A69D749402Q47203653-A7BB402C-4330-43EA-9395-3E60B6374D90Q47555039-D90B2B4C-B8CF-4B9C-B4E7-0E6A1484B064Q47595176-C64E2123-00D2-438D-BB84-4F0046634F6FQ50270442-8654D870-1F19-4576-81D8-958B62236434Q52656603-EC966505-9AF8-479B-9E3C-36042A627E78
P2860
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@ast
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@en
type
label
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@ast
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@en
prefLabel
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@ast
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@en
P2093
P2860
P1476
Safety profile of boceprevir a ...... ld experience from HCV-TARGET.
@en
P2093
Ananthakrishnan Ramani
Andrew J Muir
Benedict Maliakkal
Brian Pearlman
Curtis K Argo
David R Nelson
HCV-TARGET study group
Imtiaz Alam
Joseph K Lim
P2860
P304
P356
10.1016/J.JHEP.2014.08.052
P577
2014-09-10T00:00:00Z